Mylan N.V. (NASDAQ:MYL) had its target price increased by BTIG Research from $42.00 to $45.00 in a research note published on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently commented on MYL. Zacks Investment Research raised Mylan N.V. from a sell rating to a hold rating in a research report on Tuesday, August 1st. Royal Bank Of Canada reissued a hold rating and issued a $41.00 price target on shares of Mylan N.V. in a research report on Tuesday, June 13th. BidaskClub raised Mylan N.V. from a sell rating to a hold rating in a research report on Thursday, June 22nd. ValuEngine cut Mylan N.V. from a buy rating to a hold rating in a research report on Wednesday, June 14th. Finally, Cantor Fitzgerald assumed coverage on Mylan N.V. in a research report on Friday, June 16th. They issued a neutral rating and a $41.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $41.99.

Shares of Mylan N.V. (MYL) traded up 0.98% during mid-day trading on Wednesday, hitting $38.29. The stock had a trading volume of 6,284,973 shares. The firm has a market cap of $20.53 billion, a PE ratio of 30.95 and a beta of 1.30. The stock’s 50-day moving average price is $32.08 and its 200-day moving average price is $36.45. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period in the prior year, the firm earned $1.16 earnings per share. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. On average, analysts anticipate that Mylan N.V. will post $4.57 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Mylan N.V. (MYL) Given New $45.00 Price Target at BTIG Research” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/mylan-n-v-myl-given-new-45-00-price-target-at-btig-research/1618098.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in MYL. BlackRock Inc. raised its holdings in Mylan N.V. by 3,447.5% in the 1st quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock worth $1,513,696,000 after acquiring an additional 37,728,274 shares during the last quarter. Pzena Investment Management LLC raised its stake in Mylan N.V. by 69.9% during the 2nd quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock valued at $479,027,000 after buying an additional 5,077,371 shares during the last quarter. Vanguard Group Inc. raised its stake in Mylan N.V. by 12.0% during the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after buying an additional 3,531,974 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in Mylan N.V. by 187.3% during the 1st quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after buying an additional 2,813,653 shares during the last quarter. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management purchased a new stake in Mylan N.V. during the 2nd quarter valued at $84,364,000. Institutional investors own 71.97% of the company’s stock.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.